

Corp. Off.: 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: +9122 61933100 Fax : +91 22 61933114

Date: 17 September, 2020

To <b>BSE Limited</b> Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001	To <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400050
Scrip Code – 533543	Scrip Symbol - BROOKS

Dear Sir/ Madam,


**Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015.**

In furtherance to our disclosure letter dated 22<sup>nd</sup> July 2020, we would like to inform you that the Company has subscribed to 7963 equity shares at the face value of INR 10 each of SteriBrooks Penems Private Limited (“SteriBrooks”), amounting to 44.33% of the post issue paid-up shares capital of SteriBrooks. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated 9<sup>th</sup> September, 2015 is given in **Annexure 1** to this letter.

We request you to kindly take this in your record.

Thanking you,

Yours Sincerely  
For **BROOKS LABORATORIES LIMITED**



**Jyoti Sancheti**  
(Company Secretary and Compliance Officer)



**ANNEXURE - 1**

Details as per the Securities and Exchange Board of India circular no.CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No.	Particulars	Detail
a.	Name of the target entity, details in brief such as size, turnover etc.	SteriBrooks Penems Private Limited ("SteriBrooks")
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is one at "arms length"	Not a related party transaction.  Post-acquisition of the proposed shares of SteriBrooks, the Promoter/Promoter group of the Company will have indirect interest in SteriBrooks, as Promoter/Promoter Group of the Company.
c.	Industry to which the entity being acquired belongs	SteriBrooks is engaged in the business of the marketing and distribution of various pharmaceutical formulations outside the territory of India.
d.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line' of business of the listed entity)	For building a robust carbapenem business with integrated manufacturing capabilities.
e.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f.	Indicative time period for completion of the acquisition	Completed
g.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
h.	Cost of acquisition or the price at which the shares are acquired	INR 10 each.
i.	Percentage of shareholding / control acquired and / or number of shares acquired	44.33%
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	SteriBrooks is engaged in the business of marketing and distribution of various pharmaceutical formulations.  SteriBrooks was incorporated on 18 <sup>th</sup> June, 2020, hence it does not have any turnover history.

*Somchit*

